393 related articles for article (PubMed ID: 11507217)
1. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.
McGettigan JP; Sarma S; Orenstein JM; Pomerantz RJ; Schnell MJ
J Virol; 2001 Sep; 75(18):8724-32. PubMed ID: 11507217
[TBL] [Abstract][Full Text] [Related]
2. Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome.
McGettigan JP; Naper K; Orenstein J; Koser M; McKenna PM; Schnell MJ
J Virol; 2003 Oct; 77(20):10889-99. PubMed ID: 14512539
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
4. Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.
zur Megede J; Chen MC; Doe B; Schaefer M; Greer CE; Selby M; Otten GR; Barnett SW
J Virol; 2000 Mar; 74(6):2628-35. PubMed ID: 10684277
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a single-cycle rabies virus-based vaccine vector.
Gomme EA; Faul EJ; Flomenberg P; McGettigan JP; Schnell MJ
J Virol; 2010 Mar; 84(6):2820-31. PubMed ID: 20053743
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway.
Qiu JT; Liu B; Tian C; Pavlakis GN; Yu XF
J Virol; 2000 Jul; 74(13):5997-6005. PubMed ID: 10846081
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses.
Qiu JT; Song R; Dettenhofer M; Tian C; August T; Felber BK; Pavlakis GN; Yu XF
J Virol; 1999 Nov; 73(11):9145-52. PubMed ID: 10516021
[TBL] [Abstract][Full Text] [Related]
8. Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice.
Wang J; Shu T; Deng W; Zheng Y; Liao M; Ye X; Han L; He P; Zheng X; Li T; Feng Y; Hu F; Li P; Sun C; Chen L; Li F; Feng L
J Virol; 2021 May; 95(12):. PubMed ID: 33789991
[TBL] [Abstract][Full Text] [Related]
9. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic.
McGettigan JP; Pomerantz RJ; Siler CA; McKenna PM; Foley HD; Dietzschold B; Schnell MJ
J Virol; 2003 Jan; 77(1):237-44. PubMed ID: 12477829
[TBL] [Abstract][Full Text] [Related]
10. Development of a Live Recombinant BCG Expressing Human Immunodeficiency Virus Type 1 (HIV-1) Gag Using a pMyong2 Vector System: Potential Use As a Novel HIV-1 Vaccine.
Kim BJ; Kim BR; Kook YH; Kim BJ
Front Immunol; 2018; 9():643. PubMed ID: 29636755
[TBL] [Abstract][Full Text] [Related]
11. A recombinant non-pathogenic Leishmania vaccine expressing human immunodeficiency virus 1 (HIV-1) Gag elicits cell-mediated immunity in mice and decreases HIV-1 replication in human tonsillar tissue following exposure to HIV-1 infection.
Breton M; Zhao C; Ouellette M; Tremblay MJ; Papadopoulou B
J Gen Virol; 2007 Jan; 88(Pt 1):217-225. PubMed ID: 17170454
[TBL] [Abstract][Full Text] [Related]
12. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
J Virol; 2017 May; 91(9):. PubMed ID: 28179536
[TBL] [Abstract][Full Text] [Related]
13. Mucosal Immunization with Newcastle Disease Virus Vector Coexpressing HIV-1 Env and Gag Proteins Elicits Potent Serum, Mucosal, and Cellular Immune Responses That Protect against Vaccinia Virus Env and Gag Challenges.
Khattar SK; Manoharan V; Bhattarai B; LaBranche CC; Montefiori DC; Samal SK
mBio; 2015 Jul; 6(4):e01005. PubMed ID: 26199332
[TBL] [Abstract][Full Text] [Related]
14. Characterization of human immunodeficiency virus Gag-specific gamma interferon-expressing cells following protective mucosal immunization with alphavirus replicon particles.
Gupta S; Janani R; Bin Q; Luciw P; Greer C; Perri S; Legg H; Donnelly J; Barnett S; O'Hagan D; Polo JM; Vajdy M
J Virol; 2005 Jun; 79(11):7135-45. PubMed ID: 15890953
[TBL] [Abstract][Full Text] [Related]
15. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
16. Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine.
Wagner R; Fliessbach H; Wanner G; Motz M; Niedrig M; Deby G; von Brunn A; Wolf H
Arch Virol; 1992; 127(1-4):117-37. PubMed ID: 1456888
[TBL] [Abstract][Full Text] [Related]
17. Rabies virus-based vectors expressing human immunodeficiency virus type 1 (HIV-1) envelope protein induce a strong, cross-reactive cytotoxic T-lymphocyte response against envelope proteins from different HIV-1 isolates.
McGettigan JP; Foley HD; Belyakov IM; Berzofsky JA; Pomerantz RJ; Schnell MJ
J Virol; 2001 May; 75(9):4430-4. PubMed ID: 11287595
[TBL] [Abstract][Full Text] [Related]
18. Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.
McGettigan JP; Koser ML; McKenna PM; Smith ME; Marvin JM; Eisenlohr LC; Dietzschold B; Schnell MJ
Virology; 2006 Jan; 344(2):363-77. PubMed ID: 16226782
[TBL] [Abstract][Full Text] [Related]
19. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines.
Siler CA; McGettigan JP; Dietzschold B; Herrine SK; Dubuisson J; Pomerantz RJ; Schnell MJ
Virology; 2002 Jan; 292(1):24-34. PubMed ID: 11878905
[TBL] [Abstract][Full Text] [Related]
20. Contribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in mice.
Wong SB; Siliciano RF
J Virol; 2005 Feb; 79(3):1701-12. PubMed ID: 15650195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
